An unpleasant jab


If you had shares in Marriott International, or are someone who doesn’t want their nearest and dearest to die on a ventilator, this week was a very good week for you. It was an excellent week for Pfizer of course and a terrible week for Donald Trump, who could have used the news of a good trial result a little earlier. For most of us it was pitched in between.

So spare a thought for those poor private equity houses, possibly even sadder than the don’t-leave-your-packing-until-the-last-minut

Nothing like a good cliffhanger… care to see how the story ends?

Register with your activation code to access this story.